Home / People / Lauren Gregory
Portrait of Lauren Gregory

Lauren Gregory

Senior Associate

CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
United Kingdom
Languages English

Lauren is a European and UK Patent Attorney who specialises in the fields of molecular biology, immunology and biotechnology. Her practice focuses on patent prosecution, opposition and appeal work before the European Patent Office, including multi-party oppositions. Lauren is also experienced in the management of large European patent portfolios and associated strategic advice.

Lauren has particular expertise and interest in the areas of personalised medicine, peptide-based technology, vaccines, antisense oligonucleotides and gene therapy, antibody and antibody-conjugate technology, PCR technology, biomarkers, transgenic plant biotechnology, recombinant gene expression and stem cells.

Lauren studied natural sciences, specialising in genetics, at the University of Cambridge, and has a PhD in developmental neurobiology from University College London.

more less

Relevant experience

  • Successful defence before the EPO Opposition Division of a CuRNA, Inc patent relating to therapeutic antisense oligonucleotides, resulting in maintenance of the patent as granted.
  • Successful defence before the EPO Opposition Division of a University of Iowa Research Foundation patent relating to therapeutic complement factor H polypeptides, resulting in rejection of the opposition and maintenance of the patent as granted.
  • Experience in multiple oppositions, both offensive and defensive, including defence of large multi-party oppositions.
  • Experience in devising and advising on the prosecution strategy of large and expanding patent portfolios, as well as coordinating the prosecution in multiple countries.
  • Assisting in achieving allowance at the EPO of AbbVie’s patent claims to the dual variable domain immunoglobulin format.
  • Assisting in achieving grant at the EPO of MedImmune’s (Astra Zeneca) anti-PD1 antibody patent.
more less

Memberships & Roles

Member of CIPA and EPI

more less


2015 - Certificate in Basic Litigation Skills

2015 – EPA (European Patent Attorney)

2014 – CPA (Chartered Patent Attorney) 

2011 – PhD (Developmental Neurobiology), UCL

2007 – BA (Natural Sciences - Genetics), University of Cambridge

more less


New EPO Guidelines now pub­lished re­gard­ing amend­ing the de­scrip­tion: what’s...
In­tro­duc­tion In Oc­to­ber 2020, CMS pub­lished an art­icle ‘New EPO Guidelines ex­pec­ted re­gard­ing amend­ing a de­scrip­tion: what’s all the fuss about?’, which has been the cata­lyst for dis­cus­sion in the...
New EPO Guidelines ex­pec­ted re­gard­ing amend­ing a de­scrip­tion: what’s all...
Sum­mary The EPO re­quire­ment to amend the de­scrip­tion to con­form with al­lowed claims is chan­ging sig­ni­fic­antly. Ex­am­iners have already been giv­en in­tern­al guid­ance and re­vi­sions to the EPO Guidelines...
An EPO Case Law Round-Up: Ad­ded Mat­ter
The EPO is well-known for its strict ap­proach to as­sess­ing amend­ments un­der the ad­ded mat­ter pro­vi­sion of Art­icle 123 of the European Pat­ent Con­ven­tion. This of­ten cre­ates com­plex leg­al scen­ari­os which...
T 1621/16 - the Board of Ap­peal cla­ri­fies ad­ded mat­ter as­sess­ment with...
In the re­cent ap­peal de­cision T 1621/16 con­cern­ing Proc­tor & Gamble's ap­plic­a­tion EP 2264138, which relates to a hand dish­wash­ing li­quid, the Board of Ap­peal has provided great­er clar­ity re­gard­ing the...